Artwork

Content provided by Elsevier. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Elsevier or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Red Journal Podcast June 1, 2022

18:55
 
Share
 

Archived series ("Inactive feed" status)

When? This feed was archived on June 28, 2022 11:23 (2y ago). Last successful fetch was on May 20, 2022 17:02 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 328277275 series 1024697
Content provided by Elsevier. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Elsevier or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
June 1, 2022 RJ podcast: Three Chippy Topics in Prostate Cancer. In this month’s podcast, two Genitourinary section editors, Dr. Alison Tree, consultant clinical oncologist at The Royal Marsden and Honorary Faculty at the Institute of Cancer Research, and Dr. Daniel Spratt, Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University, join Editor-in-Chief Dr. Sue Yom to review three articles addressing cutting-edge issues in prostate cancer. The group discusses the new oral gonadotropin-releasing hormone antagonist relugolix ("An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer" at https://www.redjournal.org/article/S0360-3016(21)03240-5/fulltext), the future of MRI-based radiation dose escalation to the dominant intraprostatic lesion ("SABR for High-Risk Prostate Cancer - A Prospective Multilevel MRI-Based Dose Escalation Trial" at https://www.redjournal.org/article/S0360-3016(21)03047-9/fulltext), and an analysis from the United Kingdom’s CHHiP trial comparing disease outcomes and sexual function among patients receiving bicalutamide versus luteinizing hormone-releasing hormone analogues ("Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial" at https://www.redjournal.org/article/S0360-3016(21)03433-7/fulltext).
  continue reading

202 episodes

Artwork

Red Journal Podcast June 1, 2022

ASTRO Journals

42 subscribers

published

iconShare
 

Archived series ("Inactive feed" status)

When? This feed was archived on June 28, 2022 11:23 (2y ago). Last successful fetch was on May 20, 2022 17:02 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 328277275 series 1024697
Content provided by Elsevier. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Elsevier or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
June 1, 2022 RJ podcast: Three Chippy Topics in Prostate Cancer. In this month’s podcast, two Genitourinary section editors, Dr. Alison Tree, consultant clinical oncologist at The Royal Marsden and Honorary Faculty at the Institute of Cancer Research, and Dr. Daniel Spratt, Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University, join Editor-in-Chief Dr. Sue Yom to review three articles addressing cutting-edge issues in prostate cancer. The group discusses the new oral gonadotropin-releasing hormone antagonist relugolix ("An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer" at https://www.redjournal.org/article/S0360-3016(21)03240-5/fulltext), the future of MRI-based radiation dose escalation to the dominant intraprostatic lesion ("SABR for High-Risk Prostate Cancer - A Prospective Multilevel MRI-Based Dose Escalation Trial" at https://www.redjournal.org/article/S0360-3016(21)03047-9/fulltext), and an analysis from the United Kingdom’s CHHiP trial comparing disease outcomes and sexual function among patients receiving bicalutamide versus luteinizing hormone-releasing hormone analogues ("Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial" at https://www.redjournal.org/article/S0360-3016(21)03433-7/fulltext).
  continue reading

202 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide